Clinical Trials Directory

Trials / Conditions / Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

8 registered clinical trials studyying Relapsed/Refractory Peripheral T-cell Lymphoma — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refrac
NCT06776952
Evopoint Biosciences Inc.Phase 3
Not Yet RecruitingTo Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
NCT06702605
Evopoint Biosciences Inc.Phase 2
RecruitingExploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lym
NCT06519526
Fudan UniversityPhase 2
UnknownChi-GVM Regimen for the Treatment of R/R PTCL
NCT06211881
The First Affiliated Hospital with Nanjing Medical UniversityN/A
Active Not RecruitingA Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone
NCT05403450
Taiho Oncology, Inc.Phase 1
UnknownClinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphom
NCT05182957
The First Affiliated Hospital of Soochow UniversityPhase 2
CompletedAZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
NCT05140382
AstraZenecaPhase 2
Active Not RecruitingValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refracto
NCT04703192
Daiichi SankyoPhase 2